nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

01.03.2014 | Review Article

Could Signal Transducer and Activator of Transcription 3 be a Therapeutic Target in Obesity-Related Gastrointestinal Malignancy?

verfasst von: Katie E. O’Sullivan, John V. Reynolds, Ciara O’Hanlon, Jacintha N. O’Sullivan, Joanne Lysaght

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A large body of evidence has implicated the signal transducer and activator of transcription (STAT) family and particularly the ubiquitously expressed STAT3 protein in the pathogenesis of colorectal, hepatocellular, gastric and pancreatic carcinoma.

Discussion

Concomitantly, an increasing body of epidemiological evidence has linked obesity and its associated pro-inflammatory state with the development of gastrointestinal cancers. Visceral adipose tissue is no longer considered inert and is known to secrete a number of adipocytokines such as leptin, interleukin (IL)-6, IL-8, IL-1β and tumour necrosis factor-alpha (TNF-α) into the surrounding environment. Interestingly, these adipocytokines are strongly linked with the Janus kinase (JAK)/STAT pathway of signal transduction and there is experimental evidence linking IL-1β, IL-8 and TNF-α to JAK/STAT signaling in other tissues. The result is an up-regulation of a wide range of anti-apoptotic, pro-metastatic and pro-angiogenic genes and processes. This is particularly relevant for gastrointestinal malignancy as these factors have the potential to signal adjacent endothelial cells in a paracrine manner.

Conclusion

This review examines the potential role of the STAT3 signaling pathway in the pathogenesis of obesity-related gastrointestinal malignancy and the potential therapeutic role of STAT3 blockade given its status as a signaling hub for a number of inflammatory adipocytokines.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM (2020), “GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide: IARC CancerBase No. 10”, Lyon, France: International Agency for Research on Cancer; 2010.

Kaidar-Person O, Bar-Sela G, Person B. The two major epidemics of the twenty-first century: obesity and cancer. Obes Surg. 2011;21(11):1792–7.PubMed

Reeves GK et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.PubMedCentralPubMed

Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67(3):253–6.PubMed

Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nature Rev Cancer. 2004;4(2):97–105.

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev Cancer. 2009;9(11):798–809.

Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21.PubMed

Stark GR et al. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–64.PubMed

Lim CP, Cao X. Structure, function, and regulation of STAT proteins. Mol BioSyst. 2006;2(11):536–50.PubMed

10.

Mao X et al. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell. 2005;17(6):761–71.PubMed

11.

Xu X, Sun YL, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science. 1996;273(5276):794–7.PubMed

12.

Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998;394(6689):145–51.PubMed

13.

Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol. 2000;47:113–74.PubMed

14.

Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Ann Rev Immunol. 1998;16:293–322.

15.

Lin JX et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity. 1995;2(4):331–9.PubMed

16.

Meraz MA et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84(3):431–42.PubMed

17.

Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30(2):88–106.PubMedCentralPubMed

18.

Kisseleva T et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24.PubMed

19.

Schindler C, Darnell Jr JE. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann Rev Biochem. 1995;64:621–51.PubMed

20.

Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. BioEssays: news and reviews in molecular. Cell Dev Biol. 1999;21(1):47–52.

21.

Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059–63.PubMed

22.

Mantovani A et al. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMed

23.

Prigge JR, Schmidt EE. Interaction of protein inhibitor of activated STAT (PIAS) proteins with the TATA-binding protein, TBP. J Biol Chem. 2006;281(18):12260–9.PubMedCentralPubMed

24.

Chung CD et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278(5344):1803–5.PubMed

25.

Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer—more than a “gut” feeling? Cell Div. 2010;5:14.PubMedCentralPubMed

26.

Wegenka UM et al. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol. 1993;13(1):276–88.PubMedCentralPubMed

27.

Zhong Z, Wen Z, Darnell Jr JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95–8.PubMed

28.

Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res. 2011;31(1):33–40.PubMedCentralPubMed

29.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.PubMed

30.

Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11–9.PubMedCentralPubMed

31.

Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.PubMed

32.

Lee H et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15(4):283–93.PubMedCentralPubMed

33.

Ogura H et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008;29(4):628–36.PubMed

34.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed

35.

Ernst M, Putoczki TL. Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol. 2012;39(8):711–8.PubMed

36.

Turkson J et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18(5):2545–52.PubMedCentralPubMed

37.

Caldenhoven E et al. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem. 1996;271(22):13221–7.PubMed

38.

Bromberg JF et al. Stat3 as an oncogene. Cell. 1999;98(3):295–303.PubMed

39.

Niu G et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59(20):5059–63.PubMed

40.

Catlett-Falcone R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105–15.PubMed

41.

Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159(10):4720–8.PubMed

42.

Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer. 1999;83(4):564–70.PubMed

43.

Garcia R et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast a. carcinoma cells. Oncogene. 2001;20(20):2499–513.PubMed

44.

Grandis JR et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest. 1998;102(7):1385–92.PubMedCentralPubMed

45.

Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000;19(21):2607–11.PubMed

46.

Cai L et al. Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur J Obstet Gynecol Reprod Biol. 2010;148(1):73–80.PubMed

47.

Gao L et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res. 2005;11(17):6333–41.PubMed

48.

Gao L et al. Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells. Int J Radiat Oncol Biol Phys. 2010;77(4):1223–31.PubMed

49.

Li X et al. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells. Oncol Rep. 2010;23(2):345–53.PubMed

50.

Lysaght J et al. T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Brit J Surg. 2011;98(7):964–74.PubMed

51.

Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006;116(1):33–5.PubMedCentralPubMed

52.

Donohoe CL et al. Obesity and gastrointestinal cancer. Brit J Surg. 2010;97(5):628–42.PubMed

53.

Margetic S et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11):1407–33.PubMed

54.

Lysaght J et al. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett. 2011;312(1):62–72.PubMed

55.

Baumann H et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A. 1996;93(16):8374–8.PubMedCentralPubMed

56.

Morton NM et al. Leptin action in intestinal cells. J Biol Chem. 1998;273(40):26194–201.PubMed

57.

Barrenetxe J et al. Distribution of the long leptin receptor isoform in brush border, basolateral membrane, and cytoplasm of enterocytes. Gut. 2002;50(6):797–802.PubMedCentralPubMed

58.

Dalwadi H et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005;11(21):7674–82.PubMed

59.

Francois F et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut. 2008;57(1):16–24.PubMed

60.

Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignancies. Obes Rev. 2010;11(12):863–74.PubMed

61.

Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun. 1996;224(2):522–7.PubMed

62.

Mix H et al. Expression of leptin and leptin receptor isoforms in the human stomach. Gut. 2000;47(4):481–6.PubMedCentralPubMed

63.

Morton NM et al. Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J Mol Endocrinol. 1999;22(2):173–84.PubMed

64.

Uchiyama T et al. Leptin receptor is involved in STAT3 activation in human colorectal adenoma. Cancer Sci. 2011;102(2):367–72.PubMed

65.

Uchiyama T et al. Role of the long form leptin receptor and of the STAT3 signaling pathway in colorectal cancer progression. Int J Oncol. 2011;39(4):935–40.PubMed

66.

Saxena NK et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67(6):2497–507.PubMedCentralPubMed

67.

Pai R et al. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun. 2005;331(4):984–92.PubMed

68.

Aparicio T et al. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut. 2005;54(8):1136–45.PubMedCentralPubMed

69.

Hardwick JC et al. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121(1):79–90.PubMed

70.

Hoda MR et al. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Brit J Surg. 2007;94(3):346–54.PubMed

71.

Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1–38.PubMed

72.

Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30(9):1005–14.PubMedCentralPubMed

73.

Heinrich PC et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297–314.PubMedCentralPubMed

74.

Shirota K et al. Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;58(4):303–8.PubMed

75.

Schneider MR et al. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000;151(1):31–8.PubMed

76.

Leu CM et al. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 2003;22(49):7809–18.PubMed

77.

Block KM et al. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41(5):773–81.PubMedCentralPubMed

78.

Okitsu K et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Gene Chromosome Cancer. 2010;1(8):859–67.

79.

Lesina M et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456–69.PubMed

80.

Liu H et al. Molecular dissection of human oncostatin M-mediated signal transductions through site-directed mutagenesis. Int J Mol Med. 2009;23(2):161–72.PubMed

81.

Hermanns HM, Radtke S, Haan C, Tavernier J, Heinrich PC, et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. J Immunol. 1999;163(12):6651–8.PubMed

82.

Stephens JM, Lumpkin SJ, Fishman JB. Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes. J Biol Chem. 1998;273(47):31408–16.PubMed

83.

Migita K et al. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther. 2011;13(3):R72.PubMedCentralPubMed

84.

Balhoff JP, Stephens JM. Highly specific and quantitative activation of STATs in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 1998;247(3):894–900.PubMed

85.

Lin SK et al. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Arthritis Rheum. 2004;50(3):785–93.PubMed

86.

Kok SH et al. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum. 2009;60(5):1451–62.PubMed

87.

Fossey SL et al. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011;11:125.PubMedCentralPubMed

88.

Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol. 2001;166(5):3491–8.PubMed

89.

Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–147.PubMed

90.

Park JI et al. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine. 2005;29(3):125–34.PubMed

91.

Samavati L et al. STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol. 2009;46(8–9):1867–77.PubMed

92.

Shankar E et al. High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-kappaB. Prostate. 2012;72(3):233–43.PubMedCentralPubMed

93.

Biswas SK, Sodhi A. Tyrosine phosphorylation-mediated signal transduction in MCP-1-induced macrophage activation: role for receptor dimerization, focal adhesion protein complex and JAK/STAT pathway. Int Immunopharmacol. 2002;2(8):1095–107.PubMed

94.

Biswas P et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood. 1998;91(1):258–65.PubMed

95.

Jougasaki M et al. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Brit J Pharmacol. 2010;159(6):1294–303.

96.

Pitroda SP et al. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PloS One. 2012;7(10):e46104.PubMedCentralPubMed

97.

Miscia S et al. Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth Differ. 2002;13(1):13–8.PubMed

98.

Loetscher H et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990;61(2):351–9.PubMed

99.

Liu Z et al. Diet-induced obesity elevates colonic TNF-alpha in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J Nutr Biochem. 2012;23(10):1207–13.PubMed

100.

Jain SS, AshokKumar M, Bird RP. Differential expression of TNF-alpha signaling molecules and ERK1 in distal and proximal colonic tumors associated with obesity. Tumour Biol. 2011;32(5):1005–12.PubMed

101.

Ning Y et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128(9):2038–49.PubMedCentralPubMed

102.

Kim CS et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30(9):1347–55.

103.

Bruun JM et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab. 2004;286(1):E8–E13.PubMed

104.

Abolhassani M et al. Leptin receptor-related immune response in colorectal tumors: the role of colonocytes and interleukin-8. Cancer Res. 2008;68(22):9423–32.PubMed

105.

Cacev T et al. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis. 2008;29(8):1572–80.PubMed

106.

Wilson AJ, Byron K, Gibson PR. Interleukin-8 stimulates the migration of human colonic epithelial cells in vitro. Clin Sci. 1999;97(3):385–90.PubMed

107.

Shi Q et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res. 1999;5(11):3711–21.PubMed

108.

Hussain F et al. The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine. 2010;49(2):134–40.PubMed

109.

Kitadai Y et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Clin Pathol. 1998;152(1):93–100.

110.

Jenkins GJ et al. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. Am J Clin Pathol. 2007;60(11):1232–7.

111.

Fitzgerald RC et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut. 2002;51(3):316–22.PubMedCentralPubMed

112.

Trevino JG et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 2005;65(16):7214–22.PubMed

113.

Gharavi NM et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem. 2007;282(43):31460–8.PubMed

114.

Burger M et al. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 2005;24(12):2067–75.PubMed

115.

Oka M et al. Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Clin Exp Dermatol. 2010;19(8):e50–5.

116.

Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735–41.PubMed

117.

Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. BioEssays. 1999;21(1):47–52.PubMed

118.

Turkson J et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443–55.PubMed

119.

Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat. 2011;21(1):65–83.PubMed

120.

Ren Z et al. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett. 2003;13(4):633–6.PubMed

121.

Song H et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A. 2005;102(13):4700–5.PubMedCentralPubMed

122.

Xu X et al. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009;4(3):e4783.PubMedCentralPubMed

123.

Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol. 2008;12(4):464–71.PubMed

124.

Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Invest Drugs. 2009;18(1):45–56.

125.

Gunning PT et al. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. ChemBioChem. 2008;9(17):2800–3.PubMedCentralPubMed

126.

Turkson J et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 2004;3(12):1533–42.PubMed

127.

Zhang X et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010;79(10):1398–409.PubMedCentralPubMed

128.

University of Pittsburgh. STAT3 decoy in head and neck cancer. NCT00696176.

129.

Leong PL et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100(7):4138–43.PubMedCentralPubMed

130.

Sen M et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009;63(6):983–95.PubMedCentralPubMed

131.

M.D. Anderson Cancer Center (2012) STAT3 inhibitor for solid tumors. Accessed: 1 Oct 2012.

132.

Wang S, Chen J, Zhao Y, et al. (2010) Stat3 inhibitors and therapeutic methods using the same. (WO10077589).

133.

Chen J et al. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med Chem Lett. 2010;1(2):85–9.PubMedCentralPubMed

134.

Jones G et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biolf. 1997;267(3):727–48.

135.

Sebti SM, Hamilton AD, Turkson J, et al. (2008) Use of SH2 Stat3/Stat1 peptidomimetics as anticancer drugs. (WO08070833).

136.

Michejda, C. J., Tarasova NI, Timofeeva O, et al. (2008) Peptide-based STAT inhibitor. (WO08151037).

137.

Timofeeva OA et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol. 2007;2(12):799–809.PubMed

Titel: Could Signal Transducer and Activator of Transcription 3 be a Therapeutic Target in Obesity-Related Gastrointestinal Malignancy?
verfasst von: Katie E. O’Sullivan
John V. Reynolds
Ciara O’Hanlon
Jacintha N. O’Sullivan
Joanne Lysaght
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2014
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-013-9555-x

Springer Medizin

Could Signal Transducer and Activator of Transcription 3 be a Therapeutic Target in Obesity-Related Gastrointestinal Malignancy?

Abstract

Introduction

Discussion

Conclusion

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Expression of MT2 Receptor in Patients with Gastric Adenocarcinoma and its Relationship with Clinicopathological Features

Ampulla of Vater Adenocarcinoma in a BRCA2 Germline Mutation Carrier

The Role of Cirrhosis in the Etiology of Hepatocellular Carcinoma

Extra-skeletal Osteosarcoma Presenting as a Peri-ampullary Mass

ERCC1 in Advanced Biliary Tract Cancer Patients Treated with Chemotherapy: Prognostic and Predictive Roles

Efficacy of Endoscopic Submucosal Dissection for Cancer of the Operated Stomach

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie